Quarterly report [Sections 13 or 15(d)]

Balance Sheet Components

v3.26.3
Balance Sheet Components
9 Months Ended
Sep. 30, 2026
Balance Sheet Components [Abstract]  
Balance Sheet Components

5. Balance Sheet Components

 

Prepaid expenses and other current assets as of December 31, 2025 and September 30, 2026 consisted of the following (in thousands):

 

    As of     As of  
    December 31,     September 30,  
    2025     2026  
             
Prepaid directors’ and officers’ liability insurance premiums   $ 332     $ 607  
Prepaid drug manufacturing supply costs     6,189       7,602  
Other     1,171       1,978  
Total   $ 7,692     $ 10,187  

 

Property and equipment as of December 31, 2025 and September 30, 2026 consisted of the following (in thousands):

 

    As of     As of  
    December 31,     September 30,  
    2025     2026  
             
Leasehold improvements   $ 65     $ 43  
Lab equipment     26       26  
Construction in progress     -       213  
Furniture and fixtures     47       44  
Subtotal     138       326  
Less accumulated depreciation     (72 )     (71 )
Net   $ 66     $ 255  

 

Depreciation expense was immaterial for the nine months ended September 30, 2026 and 2025 and is included in general and administrative expenses.

 

Accounts payable as of December 31, 2025 and September 30, 2026 consisted of the following (in thousands):

 

    As of     As of  
    December 31,     September 30,  
    2025     2026  
             
Trade accounts payable   $ 301     $ 917  
Credit card liability     82       113  
Total   $ 383     $ 1,030  

 

Accrued liabilities as of December 31, 2025 and September 30, 2026 consisted of the following (in thousands):

 

    As of     As of  
    December 31,     September 30,  
    2025     2026  
             
Accrued labor costs   $ 329     $ 1,859  
Accrued drug development costs     753       614  
Other     441       907  
Total   $ 1,523     $ 3,380